Short Interest in Orion Oyj (OTCMKTS:ORINY) Expands By 20.0%

Orion Oyj (OTCMKTS:ORINY) was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 600 shares, a growth of 20.0% from the February 13th total of 500 shares. Based on an average daily trading volume, of 700 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.0% of the company’s shares are short sold.

Orion Oyj Stock Performance

OTCMKTS:ORINY remained flat at $29.76 during mid-day trading on Tuesday. The company’s stock had a trading volume of 115 shares, compared to its average volume of 3,410. Orion Oyj has a 1 year low of $17.50 and a 1 year high of $30.25. The company has a fifty day moving average price of $26.81 and a two-hundred day moving average price of $25.49. The company has a current ratio of 2.42, a quick ratio of 1.41 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $8.40 billion, a price-to-earnings ratio of 23.62 and a beta of 0.25.

Orion Oyj (OTCMKTS:ORINY) last released its earnings results on Tuesday, February 25th. The company reported $0.28 earnings per share for the quarter. The firm had revenue of $463.41 million for the quarter. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%. Equities analysts forecast that Orion Oyj will post 1.18 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Nordea Equity Research lowered Orion Oyj to a “hold” rating in a research note on Tuesday, February 4th.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.